TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.
Brief Summary: Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. The duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. The investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Options:
A: Arm Label: Palonosetron group; Type: N/A; Interventions: N/A | Arm Label: Granisetron group; Type: N/A; Interventions: N/A | Arm Label: Ramosetron group; Type: N/A; Interventions: N/A
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: Ramosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramosetron | Intervention Type: DRUG; Name: Ramosetron; Assigned to Arm(s): Ramosetron
D: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.
Brief Summary: Recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. The duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. Nausea and vomiting occur mainly on the day of operation. Glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. The investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Options:
A: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic NaCl | Arm Label: dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone phosphate | Intervention Type: DRUG; Name: dexamethasone phosphate; Assigned to Arm(s): dexamethasone | Intervention Type: DRUG; Name: Isotonic NaCl; Assigned to Arm(s): Placebo
C: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A
D: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Brief Summary: Delirium is a medical term or condition that includes a temporary inability to focus attention and to think clearly. Delirium occurs commonly (10% to 70%) in patients older than 60 undergoing large surgeries. The purpose of this study is to test rigorously whether a drug called ketamine can decrease the chance that patients will experience delirium after their surgery. The investigators are also testing whether ketamine decreases postoperative pain, postoperative opioid consumption, postoperative nausea and vomiting, ICU and hospital length of stay, and adverse outcomes (e.g. hallucinations and nightmares).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: donepezil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
C: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)
D: Arm Label: Sugammadex; Type: EXPERIMENTAL; Interventions: Drug: Sugammadex | Arm Label: Neostigmine/glycopyrrolate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neostigmine, Drug: Glycopyrrolate | Intervention Type: DRUG; Name: Sugammadex; Assigned to Arm(s): Sugammadex | Intervention Type: DRUG; Name: Neostigmine; Assigned to Arm(s): Neostigmine/glycopyrrolate | Intervention Type: DRUG; Name: Glycopyrrolate; Assigned to Arm(s): Neostigmine/glycopyrrolate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Brief Summary: Delirium is a medical term or condition that includes a temporary inability to focus attention and to think clearly. Delirium occurs commonly (10% to 70%) in patients older than 60 undergoing large surgeries. The purpose of this study is to test rigorously whether a drug called ketamine can decrease the chance that patients will experience delirium after their surgery. The investigators are also testing whether ketamine decreases postoperative pain, postoperative opioid consumption, postoperative nausea and vomiting, ICU and hospital length of stay, and adverse outcomes (e.g. hallucinations and nightmares).


Options:
A: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ketamine | Intervention Type: DRUG; Name: ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)
D: Arm Label: C group; Type: PLACEBO_COMPARATOR; Interventions: Drug: NS infusion | Arm Label: KET group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine infusion | Intervention Type: DRUG; Name: Ketamine infusion; Assigned to Arm(s): KET group | Intervention Type: DRUG; Name: NS infusion; Assigned to Arm(s): C group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients
Brief Summary: End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality. Cardiovascular (CV) causes account for almost half of all-cause mortality. Increased left ventricular mass (LVM) is a common finding in ESRD patients on dialysis and is an independent predictor of survival. Yet, to date there is no established medical treatment to reduce CV morbidity and mortality in ESRD patients on hemodialysis. Blockade of aldosterone action by means of mineralocorticoid receptor antagonists (MRA) provides cardioprotection and improves outcome in heart failure patients. Furthermore, the MRA spironolactone has recently been shown to reduce LVM in patients with mild-to-moderate chronic kidney disease (CKD). The investigators here hypothesize that spironolactone treatment is cardioprotective by reducing LVM in ESRD patients on dialysis.


Options:
A: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo Oral Tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Spironolactone 25 MG Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone 25Mg Tablet | Intervention Type: DRUG; Name: Spironolactone 25Mg Tablet; Assigned to Arm(s): Spironolactone 25 MG Tablet | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Oral Tablet
C: Arm Label: Eplerenone group; Type: EXPERIMENTAL; Interventions: Drug: Eplerenone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolactone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
Brief Summary: This study will implement and test the effectiveness and cost-effectiveness of a tobacco cessation intervention (Academic Detailing + Integrated Tobacco Order Set - AD + ITOS) for adults admitted to the hospital. The intervention will begin during the hospital stay and continue after discharge. The intervention will use resources easily available to most acute care hospitals: computerized physician order entry, physician and nurse education, staff meetings for physicians, nurses and allied health professionals, online learning capabilities, faxing to primary care providers (PCPs), and the telephone counseling and support available from a state smokers' quitline (QL).

The investigators hypothesize that the subjects in the intervention arm (AD + ITOS) will be more likely to achieve tobacco abstinence at 12 months post hospital stay than subjects in the control arm (Academic Detailing - AD). Tobacco abstinence will be assessed by self report and biochemical verification (exhaled carbon monoxide reading).


Options:
A: Intervention Type: DEVICE; Name: Real time computer prompted trauma algorithms; Assigned to Arm(s): N/A
B: Arm Label: Academic Detailing (AD); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AD + Integrated Tobacco Order Set; Type: EXPERIMENTAL; Interventions: Other: AD + Integrated Tobacco Order Set | Intervention Type: OTHER; Name: AD + Integrated Tobacco Order Set; Assigned to Arm(s): AD + Integrated Tobacco Order Set
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: computer-based decision support for asthma management | Intervention Type: DEVICE; Name: computer-based decision support for asthma management; Assigned to Arm(s): 2
D: Arm Label: e-POCT; Type: EXPERIMENTAL; Interventions: Other: Management of febrile children using e-POCT | Arm Label: ALMANACH; Type: ACTIVE_COMPARATOR; Interventions: Other: Management of febrile children using ALMANACH | Arm Label: Routine practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Management of febrile children using e-POCT; Assigned to Arm(s): e-POCT | Intervention Type: OTHER; Name: Management of febrile children using ALMANACH; Assigned to Arm(s): ALMANACH

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Cranberry Capsules for UTI Prevention in Nursing Home Residents
Brief Summary: Urinary tract infection (UTI) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. The primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacteriuria plus pyuria in female nursing home residents. These aims will be accomplished by conducting a double blind randomized placebo controlled efficacy trial of two oral cranberry capsules daily versus placebo in a cohort of Connecticut female nursing home residents.


Options:
A: Arm Label: Cranberry-lingonberry juice; Type: EXPERIMENTAL; Interventions: Other: Cranberry-lingonberry juice | Arm Label: Placebo juice; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo juice | Intervention Type: OTHER; Name: Cranberry-lingonberry juice; Assigned to Arm(s): Cranberry-lingonberry juice | Intervention Type: OTHER; Name: Placebo juice; Assigned to Arm(s): Placebo juice
B: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cranberry juice | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo juice | Intervention Type: BIOLOGICAL; Name: Cranberry juice; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: Placebo juice; Assigned to Arm(s): B
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: WelTract | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: WelTract; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Cranberry Capsules for UTI Prevention in Nursing Home Residents
Brief Summary: Urinary tract infection (UTI) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. The primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacteriuria plus pyuria in female nursing home residents. These aims will be accomplished by conducting a double blind randomized placebo controlled efficacy trial of two oral cranberry capsules daily versus placebo in a cohort of Connecticut female nursing home residents.


Options:
A: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Cranberry Capsules for UTI Prevention in Nursing Home Residents
Brief Summary: Urinary tract infection (UTI) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. The primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacteriuria plus pyuria in female nursing home residents. These aims will be accomplished by conducting a double blind randomized placebo controlled efficacy trial of two oral cranberry capsules daily versus placebo in a cohort of Connecticut female nursing home residents.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
C: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
D: Arm Label: cranberry juice; Type: ACTIVE_COMPARATOR; Interventions: Other: cranberry juice | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo beverage | Intervention Type: OTHER; Name: cranberry juice; Assigned to Arm(s): cranberry juice | Intervention Type: OTHER; Name: placebo beverage; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
Brief Summary: This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.


Options:
A: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab
C: Arm Label: 1; Type: N/A; Interventions: N/A
D: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B